ES2182357T3 - Nueva utilizacion de budesonide y formoterol. - Google Patents

Nueva utilizacion de budesonide y formoterol.

Info

Publication number
ES2182357T3
ES2182357T3 ES98944373T ES98944373T ES2182357T3 ES 2182357 T3 ES2182357 T3 ES 2182357T3 ES 98944373 T ES98944373 T ES 98944373T ES 98944373 T ES98944373 T ES 98944373T ES 2182357 T3 ES2182357 T3 ES 2182357T3
Authority
ES
Spain
Prior art keywords
formoterol
budesonide
new use
active ingredient
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98944373T
Other languages
English (en)
Spanish (es)
Inventor
Carl-Axel Bauer
Jan Trofast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20408325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2182357(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2182357T3 publication Critical patent/ES2182357T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES98944373T 1997-09-19 1998-09-09 Nueva utilizacion de budesonide y formoterol. Expired - Lifetime ES2182357T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703407A SE9703407D0 (sv) 1997-09-19 1997-09-19 New use

Publications (1)

Publication Number Publication Date
ES2182357T3 true ES2182357T3 (es) 2003-03-01

Family

ID=20408325

Family Applications (2)

Application Number Title Priority Date Filing Date
ES98944373T Expired - Lifetime ES2182357T3 (es) 1997-09-19 1998-09-09 Nueva utilizacion de budesonide y formoterol.
ES02001670T Expired - Lifetime ES2266322T3 (es) 1997-09-19 1998-09-09 Nuevo uso de budesonida y formoterol.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02001670T Expired - Lifetime ES2266322T3 (es) 1997-09-19 1998-09-09 Nuevo uso de budesonida y formoterol.

Country Status (38)

Country Link
US (2) US7897646B2 (enExample)
EP (2) EP1210943B1 (enExample)
JP (1) JP2001517630A (enExample)
KR (1) KR20010024140A (enExample)
CN (1) CN1149998C (enExample)
AR (1) AR013506A1 (enExample)
AT (2) ATE222106T1 (enExample)
AU (1) AU757235B2 (enExample)
BR (1) BR9812325A (enExample)
CA (1) CA2302700C (enExample)
CY (1) CY1106156T1 (enExample)
CZ (1) CZ295250B6 (enExample)
DE (2) DE69834955T2 (enExample)
DK (2) DK1210943T3 (enExample)
EE (1) EE04297B1 (enExample)
ES (2) ES2182357T3 (enExample)
HK (1) HK1045812B (enExample)
HU (1) HUP0003848A2 (enExample)
ID (1) ID24838A (enExample)
IL (1) IL134773A (enExample)
IN (1) IN190791B (enExample)
IS (1) IS2715B (enExample)
MX (1) MXPA00002615A (enExample)
MY (1) MY127812A (enExample)
NO (1) NO327176B1 (enExample)
NZ (1) NZ503173A (enExample)
PL (1) PL190782B1 (enExample)
PT (2) PT1210943E (enExample)
RU (1) RU2199322C2 (enExample)
SA (1) SA98190773B1 (enExample)
SE (1) SE9703407D0 (enExample)
SI (2) SI1210943T1 (enExample)
SK (1) SK285330B6 (enExample)
TR (1) TR200000726T2 (enExample)
TW (1) TW546140B (enExample)
UA (1) UA72446C2 (enExample)
WO (1) WO1999015182A1 (enExample)
ZA (1) ZA988516B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
AU756852B2 (en) * 1998-11-13 2003-01-23 Jagotec Ag Dry powder for inhalation
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
MXPA03007017A (es) * 2001-02-06 2004-09-13 Innovata Biomed Ltd Medicamentos.
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
CA2500065A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
CA2615173C (en) 2005-07-14 2012-01-03 Lipothera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
JP2009519970A (ja) * 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経口投与用製薬剤形の製造方法
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
EP2077830B1 (en) * 2006-10-17 2012-11-07 Lithera, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
DK2435023T3 (en) 2009-05-29 2016-10-24 Pearl Therapeutics Inc Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta 2-adrenergic receptor agonists and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
AU2010258751A1 (en) * 2009-06-09 2012-02-02 Sunovion Respiratory Development Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
CN102000090A (zh) * 2009-08-31 2011-04-06 北京利乐生制药科技有限公司 一种以布地奈德与阿福特罗为活性成分的复方制剂
AU2011205646B2 (en) * 2010-01-15 2014-10-02 Neothetics, Inc. Lyophilized cake formulations
US9597531B2 (en) 2010-11-24 2017-03-21 Neothetics, Inc. Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
WO2012129237A2 (en) 2011-03-20 2012-09-27 Trustees Of Boston University Therapeutic agent for emphysema and copd
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
ES2712988T5 (es) 2013-03-15 2022-10-21 Pearl Therapeutics Inc Métodos y sistemas para acondicionamiento de materiales cristalinos en partículas
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
WO2015065220A1 (ru) * 2013-10-28 2015-05-07 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201321712D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
US11559505B2 (en) 2015-12-04 2023-01-24 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
JP7470646B2 (ja) 2018-06-14 2024-04-18 アストラゼネカ・ユーケイ・リミテッド コルチコステロイド医薬組成物を用いて喘息の症状を治療および予防するための方法
WO2021048171A1 (en) * 2019-09-10 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
US12329759B2 (en) 2019-10-17 2025-06-17 Trustees Of Boston University Methods and compositions relating to lung function

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235222A (en) 1989-09-08 1992-11-25 Glaxo Group Ltd Inhalatory composition comprising salmeterol and beclomethasone dipropionate
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5250286A (en) * 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
PL164294B1 (pl) 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5444521A (en) 1991-07-15 1995-08-22 Canon Kabushiki Kaisha Image fixing device capable of controlling heating overshoot
EP1101493A3 (en) 1991-12-18 2004-01-14 AstraZeneca AB New combination of formoterol and budesonide
HU0004452D0 (enExample) * 1991-12-18 2001-01-29 Astra Ab
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
GB9519692D0 (en) * 1995-09-27 1995-11-29 Quillin Helen Atomising nozzle
DE69634416T2 (de) * 1995-11-24 2005-12-29 Glaxosmithkline S.P.A. Chinolin-derivate
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
WO1999000134A1 (en) 1997-06-27 1999-01-07 Astra Aktiebolag (Publ) New combination of antiasthma medicaments
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination

Also Published As

Publication number Publication date
JP2001517630A (ja) 2001-10-09
KR20010024140A (ko) 2001-03-26
RU2199322C2 (ru) 2003-02-27
IL134773A (en) 2005-03-20
ZA988516B (en) 1999-03-19
IS2715B (is) 2011-02-15
SE9703407D0 (sv) 1997-09-19
EE04297B1 (et) 2004-06-15
UA72446C2 (uk) 2005-03-15
NO327176B1 (no) 2009-05-04
NO20001401L (no) 2000-03-17
PT1210943E (pt) 2006-09-29
EP1210943A1 (en) 2002-06-05
MXPA00002615A (es) 2002-04-24
MY127812A (en) 2006-12-29
PL190782B1 (pl) 2006-01-31
DK1210943T3 (da) 2006-09-18
SA98190773B1 (ar) 2006-10-02
CN1271287A (zh) 2000-10-25
EP1210943B1 (en) 2006-06-14
SK3892000A3 (en) 2000-12-11
HK1045812A1 (en) 2002-12-13
US20020042404A1 (en) 2002-04-11
PL339295A1 (en) 2000-12-04
SI1210943T1 (sl) 2006-10-31
DE69807239D1 (de) 2002-09-19
CA2302700C (en) 2010-11-23
DE69834955D1 (de) 2006-07-27
IN190791B (enExample) 2003-08-23
CZ2000950A3 (cs) 2000-06-14
BR9812325A (pt) 2000-09-05
EP1014993B1 (en) 2002-08-14
SK285330B6 (sk) 2006-11-03
DE69834955T2 (de) 2007-01-25
CZ295250B6 (cs) 2005-06-15
AU757235B2 (en) 2003-02-06
HK1045812B (en) 2006-12-22
TR200000726T2 (tr) 2000-09-21
ID24838A (id) 2000-08-24
CY1106156T1 (el) 2011-06-08
AU9192898A (en) 1999-04-12
IL134773A0 (en) 2001-04-30
HUP0003848A2 (hu) 2001-08-28
IS5407A (is) 2000-03-15
TW546140B (en) 2003-08-11
CA2302700A1 (en) 1999-04-01
PT1014993E (pt) 2002-12-31
EE200000145A (et) 2001-02-15
ES2266322T3 (es) 2007-03-01
NZ503173A (en) 2001-08-31
US20060189587A9 (en) 2006-08-24
US8461211B2 (en) 2013-06-11
AR013506A1 (es) 2000-12-27
EP1014993A1 (en) 2000-07-05
DE69807239T2 (de) 2003-04-10
WO1999015182A1 (en) 1999-04-01
CN1149998C (zh) 2004-05-19
DK1014993T3 (da) 2002-11-11
ATE329599T1 (de) 2006-07-15
US20110097282A1 (en) 2011-04-28
ATE222106T1 (de) 2002-08-15
US7897646B2 (en) 2011-03-01
SI1014993T1 (en) 2003-02-28
NO20001401D0 (no) 2000-03-17

Similar Documents

Publication Publication Date Title
ES2182357T3 (es) Nueva utilizacion de budesonide y formoterol.
BR0107869A (pt) Composições farmacêuticas eletrogiradas
GT199800126A (es) Terapia de combinacion.
ES2159591T3 (es) Composicion de liberacion controlada.
SE9603669D0 (sv) New combination
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
FI971776A7 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
ID27504A (id) Formulasi oral baru
ES2235311T8 (es) Formulación de budesónida/formoterol para inhalación que tiene una densidad aparente de vertido de 0,30 a 0,36 g/ml, un proceso para preparar la formulación y el uso de la misma.
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
DE69942154D1 (de) Medikamenthaltige zusammensetzung in aerosolform
IS4394A (is) Meðferðaefnasambönd, lyfjafræðilega hæf sölt og samsetningar sem innihalda efnasamböndin, ásamt notkun þeirra
DE69932510D1 (de) Vaskularisierungsinhibitoren
ES2089357T3 (es) Formulacion medicinal en forma de aerosol.
ES2105605T3 (es) Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas.
ITRM950273A0 (it) Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni farmaceutiche.
TR199700735T1 (xx) �ste�e g�re azt,DD1 ya da DDC ile birlikte ters transkritaz inhibit�r� 3T ve HIV proteaz inhibit�r� indinavirin kullan�lmas�yla HIV enfeksiyoun i�in bir arada terapi.
ES2060293T3 (es) Nueva sustancia antiulcerosa.
ES2152315T3 (es) Xamoneline tartrato.
ES2131482A1 (es) Formulacion acuosa de bambuterol.
AR017215A1 (es) Composiciones que contienen generadores de oxido nitrico y uso de dichos generadores para la preparacion de un medicamento util para el tratamiento detrastornos de ojo seco
WO2002036105A3 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
ATE264056T1 (de) Neue flüssigformulierungen
ES2186909T3 (es) Agentes antipaludicos y antibabesiosis y composiciones farmaceuticas que los contienen.
AR006437A1 (es) Uso de monohidrocloruro de n-(endo-9-metil-9-azabiciclo [3.3.1]non-3-il)-1- metilimidazol-3-carboxamida, para la fabricacion de un medicamento para eltratamiento o la profilaxis de diarrea y una composicion farmaceutica que lo contiene